氨磺必利治疗精神分裂症的疗效及安全性分析

Analysis of the efficacy and safety of amisulpride in the treatment of schizophrenia

目的:探索分析应用氨磺必利治疗精神分裂症临床效果及其安全性。方法:选择我院收治的精神分裂症患者作为研究对象并进行分组治疗,对照组应用利培酮进行治疗,研究组应用氨磺必利进行治疗。将两组临床疗效进行对比。结果:治疗8周后,两组患者的卡尔加精神分裂症抑郁量表(CDSS)以及阳性阴性症状量表(PANSS)均有减分,研究组减分情况显著多于对照组(P<0.05)。两组患者总有效率组间差异无统计学意义(P>0.05)。两组患者治疗后EPS增分值、体重增加以及胰岛素抵抗指数增加组间不具有显著差异(P>0.05),研究组治疗后QTc、血糖以及泌乳素增加情况显著幅度显著低于对照组(P<0.05)。两组患者不良反应发生率组间差异不具有统计学意义(P>0.05)。结论:应用氨磺必利治疗精神分裂症,可以产生显著的效果,尤其是对抑郁症状以及阴性症状可以产生显著的效果,不良反应发生率低,安全性高,具有推广价值。

Objective： To explore the application of amisulpride in the treatment of schizophrenia clinical effect and its safety. Methods： our hospital schizophrenia patients as the research object and were divided into two groups, the control group used risperidone treatment, the study group were treated with amisulpride. Comparing the two groups of patients with clinical curative effect. Results： after 8 weeks of treatment, two groups of patientswith the Carle Depression Scale for schizophrenia （CDSS） and the positive and negative symptoms scale （PANSS） were decreased, while the study group was significantly less than control group （P〈0.05）. Two groups of patients with total efficiency differences between the groups was not statistically significant （P〉0.05）. Two groups of patients after treatment, the scores of EPS and the increase of body weight and insulin resistance index increased had not significant differences between groups （P〉0.05）, QTc of the study group after treatment, blood glucose and prolaetin increase was significantly lower than that of the control group （P〈0.05）. Two groups of patients with adverse reaction rate between the groups was not statistically significant （P〉 0.05 ）. Conclusion： the application of amisulpride in the treatment of schizophrenia, can produce significant results, especially has a significant effect ondepressive symptoms and negative symptoms and low incidence rate of adverse reaction, high safety, is worthy to be popularized and applied.